India, April 23 -- Novartis (NVS) said that the U.S. Food and Drug Administration approved Lutathera for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.
Gastroenteropancreatic neuroendocrine tumors are a rare cancer that is often unresectable and commonly diagnosed in the late stages of disease.
Lutathera is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults, and in Japan for somatostatin receptor-positive neuroendocrine tumors.
Novartis said it is invest...